Organic Active Ingredients TRIZ Cases

Core-shell microparticles with surface cavities enable localized acoustic drug release at vascular disease sites.

Targeting peripheral P2X4 receptors suppresses cough without central nervous system side effects, improving selectivity and safety.

Melatonin compositions administered to gestating dams counteract endophyte toxins in toxic forage.

Aildenafil citrate crystal form O ensures high purity and stability under harsh conditions via a water and tetrahydrofuran crystallization method.

CRISPR-modified bacteria reduce infection susceptibility by enhancing immune tolerance and balancing microbial populations.

Engineered polynucleotides recruit adenosine deaminase to edit LRRK2 RNA, resolving insufficient modulation of conventional targeting systems.

Pyrazine-2-carbonylamino substitution enables selective M3 modulation, improving voiding dysfunctions without cholinergic side effects.

Intravesical liposomal carriers deliver glycosaminoglycans to restore the bladder urothelial lining.

Segmented tablet combines immediate and sustained release layers to maintain therapeutic drug concentrations over 24 hours, improving patient compliance.

A controller adjusts ammonia decomposition rate using an electric field to regulate hydrogen generation for internal combustion engines.

Selective BAR3 agonists stimulate cAMP signaling to restore AQP2 expression, reducing polyuria without potassium depletion side effects.

Formulations containing Formula I compounds inhibit BAX-mediated cell death to maintain biological tissue viability during extended storage periods.

Derivatized atractylenolide compounds resolve the trade-off between thrombosis treatment efficacy and toxic side effects.

Withaferin A converts immunologically cold tumors to hot states, overcoming resistance to checkpoint blockers.

Ketone body and acetylcarnitine ratios identify patients likely to respond to L-carnitine, resolving diagnostic uncertainty in sepsis treatment.

Mebendazole inhibits Ras activation to delay tumor formation, overcoming ineffective long-term benefits of current therapies.

A fluorescent choline kinase inhibitor conjugate enables simultaneous diagnostic imaging and therapeutic action in cancer treatment.

siRNA silences B7-H3 mRNA via base pairing, bypassing antibody spatial constraints.

Novel sulfoximine compounds selectively inhibit O-GlcNAcase while avoiding lysosomal hexosaminidases.

Targeting the spindle assembly checkpoint bypasses defective p53 pathways, overcoming drug resistance in p53-mutated cancers.

Substituted pyridines selectively bind the TYK2 pseudokinase domain to reduce off-target effects and improve treatment outcomes for autoimmune disorders.

Targeting MST1r, RYK, and IL-17ra receptors bypasses erythropoietin contraindications in cancer-associated anemia.

Aryl lactam compounds inhibit AAK1 activity to treat neurological disorders by modulating receptor-mediated endocytosis processes.

N-acylhydrazone compounds selectively inhibit Nav1.7 and Nav1.8 channels, reducing adverse effects from non-specific blockage.

Systematic polymorph screening of GC4711 resolves the trade-off between drug stability and manufacturing complexity by selecting specific crystal structures.

Subconjunctival riboflavin injection targets the equatorial sclera for collagen crosslinking, overcoming anterior-only treatment limits.

Increasing polyamine and adipic acid content prevents lauric acid precipitation at low temperatures, maintaining formulation viscosity for stable drug delivery.

Film-forming polymer creates a reservoir in the stratum corneum to maintain prolonged vasoconstriction while preventing tingling sensations caused by ethanol.

Combining milk fat globule membrane with human milk oligosaccharides to increase nutrient bioavailability.

Laminaria japonica and Andrographis paniculata extracts inhibit viral binding and replication, addressing synthetic drug resistance and side effects.

Encapsulated 7-DHC nanoparticles deliver radiosensitizers to tumors, reducing normal tissue toxicity during radiation therapy.

Targeted nanoparticles accumulate in myeloid cells within the tumor microenvironment, enabling dynamic tracking and disruption of immunosuppressive functions.

A glycol chitosan conjugate with ginsenoside compound K forms nanosized self-aggregates that maintain stability in neutral aqueous solutions.

BH3 profiling detects NOXA priming and MCL-1 expression levels in cancer cell specimens to guide alvocidib administration decisions.

Human dendritic cell assay detects specific biomarker expression to replace animal testing with accurate in vitro predictive models.

Combining IAP antagonists with p38 or MK2 inhibitors enhances TNFα production in cancer cells.

Pyridazinyl compounds bind to and inhibit BRG1, BRM, and PB1 bromodomains to address transcriptional homeostasis alterations in cancer.

Novel inhibitors overcome resistance to known FGFR inhibitors like AZD4547 by accommodating gatekeeper mutations such as V564F and V562L.

Combining drug and organic acid particles overcomes poor aqueous solubility to improve bioavailability while a protective coating ensures shelf life stability.

Novel cyclic phosphorus prodrugs deliver active agents to the liver via cytochrome P450 enzymes.

Spirocyclic compounds selectively activate M1 and M4 receptors, reducing peripheral side effects like nausea while improving cognitive function.

MitoTAX targets mitochondrial complex I to overcome therapy resistance and reduce toxicity in HER2-positive breast cancer.

NLRP3 modulators activate the inflammasome to overcome low T-cell infiltration and improve treatment efficacy in resistant cancers.

Methotrexate-glucose conjugation improves targeted drug delivery to neoplasms while reducing systemic kidney toxicity.

A hypotonic aqueous composition with reduced chloride content supports amniotic fluid replacement.

Dendritic polypeptide nanocarriers covalently conjugate anticancer drugs and siRNAs via functional amino acid arms.

Characterizing crystalline Form 1 reduces hydrate conversion risk, improving formulation reliability for treating atopic dermatitis.

A composition combining Undaria pinnatifida sporophyll extract with purified ascidian shells delivers anti-inflammatory and cell regenerative effects.

Rubus coreanus extract binds PD-L1 on cancer cells to activate T cells, resolving side effects from non-selective chemotherapy.

Arid5a inhibitors stabilize pro-inflammatory mRNA transcripts, reducing cytokine production and alleviating autoimmune disease symptoms.

Reducing stabilizer quantities via optimized mRNA-lipid ratios lowers manufacturing costs while preserving protein integrity.

Formula I compounds degrade BET bromodomain proteins by recruiting E3 ligases, enabling sustained apoptosis in cancer cells.

Segmented dosage form uses enteric-coated gelling agent to increase viscosity upon tampering, deterring injection while maintaining immediate release.

Engineered microbes secrete mycosporine-like amino acids extracellularly, bypassing cell disruption to stabilize production yield.

Novel heteroaromatic methyl cyclic amine derivatives act as orexin receptor antagonists.

A soy-pea protein blend enriched with free leucine induces muscle protein synthesis comparable to whey protein standards.

Escalating dose cycles reduce cytokine release syndrome while maintaining high response rates in elderly patients.

Lipophilic side chains localize metallocene action to cancer cells, reducing systemic toxicity while maintaining anticancer activity.

Optimized aripiprazole patch formulation uses specific solvent ratios to achieve consistent drug flux through skin.

Double-stranded siRNA targets backspliced circular RNAs from the MAPT gene to silence expression and prevent pathological protein translation.

Nu-8 compound maintains positive charge at higher pH levels, eliminating tissue irritation from acidic formulations.

Coronin 1 modulators manage T cell homeostasis by inhibiting calcineurin phosphatase activity, preventing mycobacterial survival within macrophages.

Tricyclic gyrase compounds bind to enzymatic pockets, reducing bacterial resistance development.

Specific IL-18BP isoforms reduce neuroinflammatory responses by modulating cytokine levels to treat neurological diseases.

A pharmaceutical composition combining inulin and betaine reduces protein bound uremic toxins through metabolic modulation.

Novel phthalazinone compounds selectively inhibit PARP-1 through specific substituent patterns.

Antisense oligonucleotides target DMD pre-mRNA exons to skip mutations, restoring functional dystrophin production.

Microrheological WIE parameters resolve the trade-off between half-life and phase control in hyaluronic acid fillers.

Targeted CslF6 polypeptide mutations enhance water solubility and content, resolving low nutritional value in cereal grains.

Perinatal short-chain fructooligosaccharides modulate gut microbiota to prevent adult metabolic disorders by improving glucose homeostasis.

Segmenting Nav subtypes via parameter changes improves ion homeostasis while minimizing off-target effects for targeted therapy.

Modified chemical structures inhibit hepatitis C virus while reducing toxicity and side effects compared to prior art inhibitors.

Maresin-1 resolves chronic inflammation in spinal cord injuries by clearing neutrophils and shifting macrophages toward a pro-repair phenotype.

MicroRNA-26b, -203, and -200c delay DNA damage repair to overcome radioresistance while sparing normal tissue from toxicity.

Selective PFKFB4 inhibitors disrupt glycolytic flux and suppress tumor growth while maintaining oral bioavailability.

Administering autologous immature dendritic cells with immune checkpoint inhibitors at the ablated tumour site.

Formula I compounds inhibit PARP7 to restore interferon signaling and cause tumor regression.

Removing excipients from the formulation eliminates incompatibility and toxicity risks while maintaining chemical stability of the oily suspension.

Inhalable imatinib formulations with controlled crystal forms reduce systemic adverse events while maintaining therapeutic efficacy.

Specific compounds reduce wild-type EGFR inhibition to improve antitumor activity against exon 20 insertion mutations.

Blood cytokine profiling detects cerebral aneurysms through specific protein expression levels.

Formula I compounds inhibit CD73 to block adenosine production, reducing immunosuppression and enhancing anti-tumor immune response.

Fungal extracts block the FREP1-mediated pathway, reducing oocyst formation and parasite proliferation without triggering mosquito resistance.

Biodegradable linkers enable covalent conjugation of bioactive compounds to polymer matrices.

Synthetic lysine analogs disrupt microbial protein interactions to inhibit protozoan and fungal growth, overcoming drug resistance in malaria treatment.

Oral collagen hydrolysate acts as an active ingredient to support skin health and reduce corticosteroid dependency in atopic dermatitis management.

A single vector delivers genome editing endonucleases and therapeutic mRNA to simultaneously disrupt pathogenic genes.

Alginic acid and carrageenan reduce protein adsorption on hard contact lenses, preventing corneal abrasions while preserving tear film bactericidal function.